BIO International Convention 2024, The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, and Abu Dhabi...
Moderna's Investigational Therapeutic for Methylmalonic Acidemia (mRNA-3705) Selected by U.S. Food & Drug Administration for START Pilot Program ...
Bio-Thera Solutions , a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, announced th...
Technology transfer will strengthen South Africa’s pharmaceutical sovereignty and drastically reduce production costs, thus improving affordability...
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, has launched its M...
Sanofi is all in on AI and wants to become the first biopharma company powered by AI at scale. The company is using AI to chase the miracles of science b...
Bristol Myers Squibb announced its participation in the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and the Eur...
Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-m...
Wyost® (denosumab) and Jubbonti® (denosumab) approved by EC for all indications of denosumab reference medicines Xgeva® and Prolia® EC a...
CUPID is a Phase I safety and dosimetry study of TLX592, Telix’s investigational antibody-based targeted alpha therapy for prostate cancer. Establ...
Ribobay Pharma, a prominent Chinese biopharmaceutical contract research, development, and manufacturing organization (CRDMO), in conjuncti...
Aragen is pleased to announce that its Formulation Manufacturing Facility (FMF) has been awarded Good Manufacturing Practice (GMP) certification by the Dru...
Sciwind Biosciences Co., Ltd., a clinical stage biopharmaceutical company focused on developing treatments for metabolic disease, and HK inno.N Corporation...
Selvita S.A. announced completion of a strategic transaction in which it has acquired 100% of shares in PozLab. The closing of the transaction comes ...
© 2025 Biopharma Boardroom. All Rights Reserved.
